Teclistamab
Teclistamab is a bispecific T-cell engaging antibody used to treat relapsed or refractory multiple myeloma. It works by binding to both CD3 receptors on T-cells and BCMA on myeloma cells, redirecting T-cells to attack cancer cells. This medication is administered as a subcutaneous injection and requires monitoring for serious side effects including cytokine release syndrome and neurotoxicity.
Teclistamab is a bispecific antibody that targets multiple myeloma cells by connecting T-cells to cancer cells expressing BCMA.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01FX24
- RxNorm
- 2619426
- Generic
- Teclistamab
- Class
- atc-l01
- Brands
- Tecvayli
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- Step-up dose 1: 0.06 mg/kg, Step-up dose 2: 0.3 mg/kg, Maintenance: 1.5 mg/kg weekly
- Maximum
- consult physician
- Frequency
- weekly after step-up dosing
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- Not approved for pediatric population
- Maximum
- consult physician
- Frequency
- not_applicable
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- Step-up dose 1: 0.06 mg/kg, Step-up dose 2: 0.3 mg/kg, Maintenance: 1.5 mg/kg weekly
- Maximum
- consult physician
- Frequency
- weekly after step-up dosing
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
10 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second trimesteravoid
discontinue therapy if pregnancy occurs
fetal ultrasound monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid
avoid use near delivery due to potential neonatal effects
fetal monitoring and assessment of neonatal immune function
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid breastfeeding
do not breastfeed during treatment and for at least 3 months after last dose
no specific monitoring required
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children adolescentsnot applicable
not indicated for pediatric patients - safety and efficacy not established in patients under 18 years
not applicable
geriatric
elderly 65 and olderno specific dose adjustment required
use with caution due to higher incidence of infections and cytopenias observed in clinical trials
monitor blood counts and for signs of infection
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno dose adjustment required
no clinically significant effect on pharmacokinetics observed
routine renal function monitoring
renal_impairment
severeuse with caution
limited data available in severe renal impairment - use based on risk-benefit assessment
monitor renal function closely during treatment
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno specific adjustment
limited data available - use with caution
monitor liver function tests
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate to severenot established
use not recommended due to lack of data
monitor liver function closely
Statistics and clinical data
Drug class
Teclistamab is a bispecific antibody that binds to BCMA on myeloma cells and CD3 on T-cells
FDA approval date
FDA approved Teclistamab for treatment of adult patients with relapsed or refractory multiple myeloma
Indication
Approved indication for Teclistamab (Tecvayli)
Overall response rate
Overall response rate in patients treated with Teclistamab at recommended dose
Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
Teclistamab is a bispecific T-cell engaging antibody that binds to the CD3 receptor on T-cells and B-cell maturation antigen (BCMA) on the surface of multiple myeloma cells, redirecting and activating T-cells to destroy myeloma cells.
Requires hospitalization for initial dosing with monitoring for cytokine release syndrome (CRS) and neurotoxicity. Common side effects include cytopenias, fatigue, and infections. Healthcare providers should be trained on proper administration and management of immune-related adverse reactions.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy